Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.
Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.
Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.
Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the promotion of Andrea Matthews to Chief Business Officer, elevating her role to enhance the company’s strategic growth. Matthews, who has nearly nine years with Astria, is tasked with overseeing Corporate Strategy, Business Development, Investor Relations, Corporate Communications, and Patient Advocacy. Her leadership is expected to drive the development of STAR-0215, a monoclonal antibody in clinical trials for treating hereditary angioedema. CEO Jill C. Milne highlighted Matthews' contributions to the company’s pivotal developments. The company focuses on creating impactful therapies for rare allergic and immunological diseases.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the grant of stock options for 39,300 shares of common stock on April 3, 2023. This grant, made under the 2022 Inducement Stock Incentive Plan, targets new employees as per Nasdaq Listing Rule 5635(c)(4). The options will have an exercise price of $12.93, equivalent to the closing stock price on the grant date. Vesting occurs over four years, with 25% vesting after the first anniversary and the remainder vesting monthly for 36 months, contingent upon continued employment. Astria focuses on rare and niche immunological diseases with its lead program, STAR-0215, targeting hereditary angioedema.
Astria Therapeutics, Inc. (NASDAQ:ATXS) provided a corporate update and financial results for Q4 2022 and the full year. The company is advancing STAR-0215 for hereditary angioedema (HAE) treatment, with promising Phase 1a results showing a potential half-life of up to 117 days. The ALPHA-STAR Phase 1b/2 trial is underway, with proof-of-concept results expected in mid-2024. As of December 31, 2022, Astria reported cash and short-term investments of $226M, ensuring operational funding through mid-2025. The net loss for Q4 was $13.3M, reflecting a slight increase from the previous year.
Astria Therapeutics, Inc. (NASDAQ:ATXS) will announce its fourth quarter and full year 2022 financial results before the Nasdaq Global Market opens on March 22, 2023. CEO Jill C. Milne, Ph.D., will lead a conference call and webcast at 8:30am ET to discuss these results and provide updates on corporate developments. The company's lead program, STAR-0215, is in clinical development for hereditary angioedema. Interested parties can access the webcast through the Astria website. The announcement aims to inform investors and stakeholders of the company’s performance and future outlook.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
